On Demand | 5th International Meeting on Lung Cancer

Επιστημονικό Πρόγραμμα
Τα πιστοποιητικά είναι διαθέσιμα!
Δεν υπάρχουν διαθέσιμα δεδομένα. Επικοινωνήστε μαζί μας μέσω email ζητώντας την πιστοποίησή σας ή καλέστε μας για να σας βοηθήσουμε.

Chairs: D. Papadatos - Pastos (UK), G. Tsakonas (SWE)
09.00-09.20 Genomic profile of SCLC and treatment of LS-SCLC F. I. Dimitrakopoulos (GR)
09.20-09.40 Novel therapeutic advances in ES-SCLC Ch. Fokoloros (GR)
09.40-10.00 The future of therapeutic options in malignant mesotheliom I. Metaxas (SUI)
10.00-10.20 State of the art of Malignant Thymomas S. Gennatas (UK)
10.20-10.30 Comments/Discussion

Chairs: F. Dimitrakopoulos (GR), I.Metaxas (SUI)
11.00-11.20 The future of the treatment of ALK+ NSCLC: An update D. Thomaidou (GR)
11.20-11.40 EGFR mutant NSCLC: Overcoming the resistance to 3rd generation EGFR TKIs and new therapeutic options G. Tsakonas (SWE)
11.40-12.10 The importance of co-mutations in NSCLC N. Karachaliou (DE)
12.10-12.30 Comments/Discussion

Chairs: Ph. Koinis (GR), D. Papadatos - Pastos (UK)
12.30-12.45 Blood immunomap to predict immunotherapy responses
in lung cancer P. Verginis (GR)
12.45-13.00 Comprehensive liquid biopsy analysis as a prognostic and
diagnostic tool for lung cancer A. Markou (GR)
13.00-13.15 Liquid biopsies for Tumor Molecular Profiling using NGS G. Nasioulas (GR)
13.15-13.30 Functional and Phenotypic Analysis of Circulating Tumor Cells
(CTCs from Lung Cancer Patients) G. Kallergi (GR)
13.30-13.45 SNF-CLIMEDIN: Prospective randomised controlled trial with
digital interventions improving quality of life of NSCLC patients Th. Kosmidis (GR)
13.45-14.00 Peripheral Immune Cell Subsets as Biomarkers
in Lung Cancer Patients A. Xagara (GR)

Chairs: Ph. Koinis (GR), D. Papadatos - Pastos (UK)

Chairs: P. Savvides (US), G. Fotopoulos (CY)
16.30-16.50 Targeting Her2 & BRAF mutated NSCLC G. Ioannidis (CY)
16.50-17.10 The new landscape of ADCs in NSCLC Ph. Koinis (GR)
17.10-17.20 Comments/Discussion

Chairs: N. Karachaliou (DE), A. Kotsakis (GR)
17.40-18.10 ctDNA for the Detection of Molecular Residual Disease M. Liu (US)
18.10-18.40 The liquid biopsy as a tool for early cancer detection N. Papadopoulos (US)

Chairs: P. Christopoulos (DE), Ch. Charalambous (CY)
09.00-09.20 The fundamental need for molecular profiling of early stage NSCLC:
The EGFRm paradigm O. Fiste (GR)
09.20-09.40 Treatment of ALK early-stage NSCLC: A changed landscape A. Koulouris (SWE)
09.40-10.00 The future of oncogene-driven stage I - IIIC NSCLC with TKIs G. Fotopoulos (CY)
10.00-10.10 Comments/Discussion

Chairs: D. Papadatos - Pastos (UK), N. Panagiotopoulos(UK)
10.10-10.30 Adjuvant immunotherapy in operable NSCLC: When and for whom in
the era of NAC A. Koumarianou (GR)
10.30-10.50 The emergent value of peri-operative immunotherapy in NSCLC:
Selection criteria P. Christopoulos (DE) Sponsored by AstraZeneca
10.50-11.10 New immunotherapy combinations in early-stage NSCLC I. Mountzios (GR)
11.10-11.20 Comments/Discussion

Chairs: P. Savvides (US), E. Kefaloyannis (GR)
12.00-12.15 Treatment evolution in early-stage NSCLC P. Savvides (US)
12.15-12.30 Key selection criteria for pre-operative treatment
in early NSCLC L. Toufektzian (GR)
12.30-12.50 Case presentation #1 S. Ravanbakhsh (US)
12.50-13.10 Case presentation #2 T. Sio (US)
13.10-13.30 Case presentation #3 N. Panagiotopoulos (UK)
Panel: G. Stratakos (GR), K. Papagiannopoulos (UK), H. Gkika (DE), A. Dimopoulos (GR)

Chairs: Α. Tsaroucha (GR), A. Konstantis (UK)
14.20-14.40 Interventional Pulmonology management of malignant airway
obstruction: Palliative or Therapeutic approach? G. Stratakos (GR)
14.40-15.00 The role of cannabinoids in the management
of chronic diseases E. Azas (GR) Sponsored by Lilly Pharmaserve
15.00-15.20 OXYCODONE; bridging the gap in cancer pain management
in Greece M.- G.Αngelerou (GR)
15.20-15.30 Discussion

Chairs: Ph. Koinis (GR), N. Karachaliou (DE)
15.30-15.50 Immunotherapy: State of the art in metastatic lung cancer in
the 1st line setting in frail patient population D.Papadatos-Pastos (UK) Sponsored by Roche
15.50-16.10 Therapeutic options after immunotherapy failure Ch. Charalambous (CY)
16.10-16.30 Oligometastatic disease: Systemic treatment against
local treatment P. Economopoulou (GR)
16.30-16.40 Comments/Discussion

Chairs: A. Giatromanolaki (GR), Ch. Charalambous (CY)
16.40-17.00 Targeting NSCLC with oncogene fusions beyond ΑLK A. Dimou (US)
17.00-17.20 The therapeutic potential of cellular therapy in oncology V. Tseveleki (GR)
17.20-17.40 Homologous Recombination Deficiency: a more universal
therapeutic target in cancer

Chairs: A. Kotsakis (GR), P. Christopoulos (DE)
KRAS inhibition: What’s next F. Skoulidis (US)

Chairs: F. Dimitrakopoulos (GR), P. Christopoulos (DE)
18.50-20.00 Oral presentations
18.50-19.00 ALK disease, clinical and preclinical exploration P. Christopoulos (DE)
19.00-19.10 Genomic scarring score predicts the response to PARP inhibitors
in non-small cell lung cancer K. Tsilingiri (GR)
19.10-19.20 Spatial analysis of tumor microenvironment in
non-small cell lung cancer I. Pateras (GR)
19.20-19.30 A pilot phase 2 study of AMivantamab in pre-trEaTed patients with
advanced NSCLC harbrorιng uncommon EGFR muTationS excluding
Exon 20 inserTion mutations - The AMETHIST Trial I. Mountzios (GR)
19.30-19.40 Clinical significance of SNPs in the PDCD1 gene in NSCLC
patients treated with immunotherapy F. Dimitrakopoulos (GR)
19.40-19.50 Radiotherapy and autophagy targeting agents to enhance
HLA-class-I expression in non-small cell lung cancer M. Koukourakis (GR)
19.50-20.00 Microenvironmental immune profiling in
non-small cell lung cancer A. Giatromanolaki (GR)

Angelerou M.- G.
MSc, PhD, Pharmacist, Greece
Azas E.
Internist - Diabetologist, Assistant Director, 3rd Internal Medicine Department, Hygeia Hospital, Athens, Greece
Charalambous C.
BM (Soton) MRCP(UK) FRCR (UK), Consultant Clinical Oncologist, Bank of Cyprus Oncology Centre, Nicosia, Cyprus
Christopoulos P.
MD, PhD, Hematologist / Medical Oncologist, Thoraxklinik and National Center for Tumor Diseases (NCT) at Heidelberg University Hospital, Heidelberg, Germany
Dimitrakopoulos F. I.
MD, PhD, Medical Oncologist, Division of Oncology & Molecul ar Oncology Laboratory, Department of Medicine, Univ ersity of Patras, Greece
Dimopoulos A.
MD, PhD, Director of Radiation Oncology, Department Metropolitan Hospital, Medical University of Vienna, Estro Faculty Member
Dimou A.
MD, Senior Associate Consultant, Division of Medical Oncology, Assistant Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA
Economopoulou P.
MD, PhD, Consultant Medical Oncologist, 2nd Department of Internal Medicine, Attikon University Hospital, Greece
Fiste O.
Fellow in Medical Oncology, Medical Oncology Unit, Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece
Fokoloros Ch.
MD PhDc, Medical Advisor - Oncology Pipeline Medical Lead, Amgen Hellas
Fotopoulos G.
MD, FSMB (USA), PhD, Medical Oncology Consultant, UT Health San Antonio MD Anderson Alumni, Bank Of Cyprus Oncology Center
Gennatas S.
Consultant Medical Oncologist, Guy’ s and St. Thomas ’ NHS Foundation T rust, London, UK
Giatromanolaki A.
MD, Professor of Pathology, Medical School, Democritus Univeristy of Thrace, Alexandroupolis, Greece
Gkika E.
Assoc. Professor, Vice Chair of the department of Radiation Oncology, Universitätsklinikum Freiburg, Freiburg, Germany
Ioannidis G.
Oncology Department, Nicosia Gener al Hospital, State Health Services Organisation (SHSO) of Cypru s
Kallergi G.
Assistant Professor of Biochemistry, Department of Biology, University of Patras, Greece
Karachaliou N.
MD, PhD, Medical Director, Global Clinical Development, Merck KGaA, Darmstadt, German
Kefaloyannis Ε.
Associate Professor in Thoracic Surgery, Head of Thoracics, PAGNI, Crete, Greece
Klinakis A.
PhD, Director of Research - Professor level, Biomedical Research Foundation of the Academy of Athens, Greece
Koinis F.
MD, PhD, Assistant Professor of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
Konstantis A.
Consultant Medical Oncologist, Princess Alexandra Hospital and UCL NHS Trust, UK
Kosmidis Th.
Co-founder & CEO at Care Across. Past Assembly member of the European Commission “Mission on Cancer”, Expert In Residence at Imperial Enterprise Lab.
Kotsakis A.
MD, PhD, Associate Professor of Medical Oncology, Director of Department of Medical Oncology, University Hospital of Larisa, Thessaly, Greece
Koukourakis M.
Radiation Oncologist, Professor, Medical School, Democritus University of Thrace - Head Dept of Radiotherapy - Oncology, Radiobiology and Radiopathology Unit, Universiy Hospital of Alexandroupolis, Greece
Koulouris A.
MD, Oncologist, Theme Cancer, Karolinska University Hospital, Department of Oncology-Pathology, Karolinska Institutet, Sweden
Koumarianou A.
MD, PhD, Consultant in Medical Oncology, Hematology Oncology Unit, 4th Department of Internal Medicine, Attikon Univ ersity Hospital, Athens
Liu M.
MD, Chief Medical Officer for Oncology, Natera, Inc., USA
Markou A.
PhD, Assistant Professor, Lab of Analysis Circulating Tumor Cells (ACTC), Lab of Analytical Chemistry, Dept of Chemistry, National and Kapodistrian University of Athens, Greece
Metaxas I.
Senior Consultant Medical Oncology, Kantonsspital Münsterlingen, Münsterlingen, Switzerland
Mountzios I.
Consultant-Medical Oncologist, 2 nd Oncology Department and Clinical T rials Unit, Henry Dunant Hospital, Oncolife Institute Founder
Nasioulas G.
PhD, Chief Scientific Officer, Genekor Medical S.A., Athens, Greece
Panagiotopoulos N.
MD, PhD, Consultant Thoracic Surgeon, Honorary Clinical Associate Professor UCL, Thoracic Surgery Department, University College London Hospitals (UCLH), UK
Papadatos – Pastos D.
MRCP (UK) PhD, Consultant in Medical Oncology, Lung Cancer and Acute Oncology, University College London Hospitals and The Princess Alexandra Hospital, London, UK
Papadopoulos N.
Ph.D., Professor, Oncology and Pathology, Director of Translational Genetics, Ludwig Center for Cancer Genetics & Therapeutics, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Institutions
Papagiannopoulos K.
Senior Consultant Thoracic Surgeon Leeds, Honorary Senior Lecturer Leeds University, Past President and Treasurer European Society of Thoracic Surgeons, Director Central Fund Archdiocese of GB and Thyateira
Pateras I.
Bsc, MD, PhD, Pathologist, Assistant Professor, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Ravanbakhsh S.
MD, Thoracic Surgeon, Department of Cardiothoracic Surgery, Mayo Clinic, Arizona, USA
Savvides P.
MD, PhD, MPH, Senior Associate Consultant, Thoracic H&N Medical Oncology, Mayo Clinic Arizona, USA
Sio T.
Professor of Radiation Oncology, Mayo Clinic Arizona, Arizona, USA
Skoulidis F.
MD, PhD, Assistant Professor, Department of Thoracic and Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, U.S.A.
Stratakos G.
MD, PhD, FCCP, Professor of Respiratory Medicine and Interventional Pulmonology, National and Kapodistrian University of Athens, Head Interventional Pulmonology Unit - 1st Respir.Med.Dept, NK University of Athens, “Sotiria” Hospital, Greece, President, European Association for Bronchology and Interventional Pulmonology
Thomaidou D.
Senior Director, Global Medical Affairs, Precision Medicine, Lung Cancer, Pfizer
Toufektzian L.
Thoracic Surgeon, Director of Thoracic Surgery Department Athens Medical Center, Greece
Tsakonas G.
MD, PhD, Senior Consultant in Oncology, Senior Researher, Lung Oncology Center, Theme Cancer Oncology and Pathology Department, Karolinska University Hospital, Karolinska Institutet, Solna, Sweden
Tsaroucha A.
MD, MSc, PhD, Pulmonologist - Intensivist, Director of NHS, 2nd Pulmonary Department, Athens Chest Hospital “Sotiria”, Athens Greece
Tseveleki V.
PhD, Chief Operating Officer, Theracell Laboratories
Tsilingiri K.
PhD, Cancer Biology Laboratory, Center of Basic Research, Biomedical Research Foundation of the Academy of Athens, Greece
Verginis P.
Associate Professor Immunology, Biochemistry, School of Medicine, University of Crete, Heraklion, Greece
Xagara Α.
Molecular Biologist, PhD, Laboratory of Oncology, University of Thessaly, Larissa

Technical Support is available:
- everyday 09:00-17:00
- at the day of the event 09:00-21:00
For Technical Support please contact us:
Phone: +30 210 72 40 039
Email: support@livetime.gr

Event Details
Add to Calendar
Sponsors
Share This Event